At a glance
ClinicalIndex Comparison Record- ✓Adult age ≥18 years
- ✓Histologically-proven incurable metastatic solid tumor (excluding primary brain tumors), multiple myeloma, or B-cell non-Hodgkin lymphoma (excluding CLL, SLL, HCL)
- ✓No standard treatment known to prolong life, or patient has refused such treatment
- ✓ECOG performance status 0-2
- ✕Prior or concurrent malignancy with potential to interfere with safety or efficacy assessment
- ✕Ongoing toxicity ≥CTCAE grade 2 (except peripheral neuropathy or asymptomatic corrected biochemical toxicities) related to prior anti-tumor treatment
- ✕Ongoing peripheral neuropathy ≥CTCAE grade 3
- ✕Concurrent anti-cancer therapy (cytotoxic, biologic, radiation, hormonal) except supportive care with potential anti-cancer effect or castration-intent therapy for prostate cancer
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial
In Brief
A Phase 2 clinical trial evaluating Olaparib, Dasatinib, and 12 other interventions for Lymphoma, Non-Hodgkin and 2 related conditions. Currently recruiting, targeting 720 participants across 10 sites.
Signals
Detailed Summary
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.
Study Details
Timeline
Interventions
300mg taken twice daily
100mg administered orally once daily
* Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase. * Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.
5mg orally twice daily
500mg orally once daily
250mg orally twice daily
125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days
50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off
25mg infused over a 30-60 minute period once a week
150mg orally, once daily
Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion. Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.
Vemurafenib = 960 mg orally every 12 hours. Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest
150mg taken orally, once daily
300mg taken orally, twice daily